Skip to main content

Advertisement

Table 4 Main characteristics of the Pediatric Investigation Plans (PIPs) and related active ingredients (NCEs)

From: Does the development of new medicinal products in the European Union address global and regional health concerns?

Characteristics Num. of PIPs (%) Num. of NCEs (%)
Total 103 (100) 95 (100)
Type of intervention   
   Prevention 11 (10.7) 8 (8.4)
   Diagnosis - -
   Treatment 85 (82.5) 80 (84.2)
   Palliative care/rehabilitation 7 (6.8) 7 (7.4)
Disease seriousness   
   Serious disease 73 (70.1) 66 (69.5)
   Nonserious disease 20 (19.4) 19 (20.0)
   Risk factor for serious disease 10 (9.7) 10 (10.5)
New mechanism of action 21 (20.4) 20 (21.0)
Fixed-dose combinations 11 (10.7) 11 (11.6)
Biotechnological/biological product 31 (30.1) 25 (26.3)
Orphan medicinal product 16 (15.5) 16 (16.8)
  1. Data do not sum to 100% because of rounding errors. PIPs = Pediatric Investigation Plans. NCEs = New chemical entities with an agreed PIP. Source of the data: http://www.ema.europa.eu (search until September 2010).